The Comparison and Estimation of the Prognostic Value of Lipid Profiles in Patients With Prostate Cancer Depends on Cancer Stage Advancement.

Lipid profiles and prostate cancer have a controversial relationship, and the predictive ability of lipids in determining cancer risk estimation is still questionable. This study demonstrates a significance assessment of the plasma lipid profiles of subjects with prostate cancer. Locoregional subjects irradiated with external beam therapy were compared to prostate cancer subjects with bone metastases. The histopathologic diagnosis of 103 subjects (71 locoregional [Group 1] and 32 palliative [Group 2]) were analyzed and compared using their blood samples, total cholesterol (CHL), triglycerides (TG), high-density lipoprotein (HDL) cholesterol, and low-density lipoprotein (LDL) cholesterol. The HDL/CHL, LDL/CHL, and TG/HDL ratios were used for better fit and comparison. Subjects were grouped according to their cancer stages and assessed using statins in both groups. In this study, serum HDL/CHL was significantly increased in Group 1 compared to Group 2 ( p = .02), and time-statin factor in relation was statistically significant ( p = .02). For Group 2, this index decreased with each day after radiotherapy ( p = .07), which means the CHL was increased. Negative effects were noticed at the time of observation of the LDL/HDL ratio with an approximate increase of 0.0025 each day in palliative subjects. This ratio showed a statically significant elevation ( p = .04). There was not a statistically significant difference in the value of the TG/HDL ratio between both groups. As the survival of cancer subjects increases, frequent control of the lipid profile gains importance.